ASH: Reducing Factor XI Cuts Clots After Knee Arthroplasty

This article originally appeared here.
Share this content:
ASH: Reducing Factor XI Cuts Clots After Knee Arthroplasty
ASH: Reducing Factor XI Cuts Clots After Knee Arthroplasty

MONDAY, Dec. 8, 2014 (HealthDay News) -- Reducing factor XI levels with a second-generation antisense oligonucleotide (FXI-ASO) is effective for preventing venous thromboembolism after total knee arthroplasty, according to a study published online Dec. 7 in the New England Journal of Medicine. The findings were released to coincide with the annual meeting of the American Society of Hematology, held from Dec. 6 to 9 in San Francisco.

Harry R. Büller, M.D., from the University of Amsterdam, and colleagues conducted an open-label parallel-group study involving 300 patients undergoing elective primary unilateral knee arthroplasty. Participants were randomized to receive one of two doses of FXI-ASO (200 or 300 mg) or 40 mg of enoxaparin once daily.

The researchers found that around the time of surgery, the mean factor XI levels were 0.38, 0.20, and 0.93 units per milliliter in the 200-mg FXI-ASO, 300-mg FXI-ASO, and enoxaparin groups, respectively. The primary efficacy outcome of incidence of venous thromboembolism occurred in 27 percent of those who received the 200-mg dose of FXI-ASO, 4 percent of those who received the 300-mg dose of FXI-ASO, and 30 percent of those who received enoxaparin. Compared with enoxaparin, the 200-mg regimen was noninferior, and the 300-mg regimen was superior (P < 0.001).

"These findings support the concept that with the use of strategies targeting factor XI, thrombosis and hemostasis can be dissociated," the authors write.

The study was funded by Isis Pharmaceuticals, the manufacturer of FXI-ASO.

Abstract
Full Text
Editorial
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »